The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2018 | Future antibody avenues for cutaneous lymphoma treatment
Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, gives his insight into the novel therapies being explored for cutaneous T-cell lymphomas, including bretuximab vedotin and mogamulizumab .
